October 5, 2021
Life Sciences
  • The FDA authorized two additional COVID-19 at-home tests in an effort to continue increasing the availability of at-home tests amid shortages. The agency granted Laboratory Corporation of America an Emergency Use Authorizations for fits combined home collection kit for molecular testing for COVID-19 and influenza A/B. The kit will become available in early October and can be ordered by an individual’s physician. The FDA also authorized ACON Laboratories’ rapid, at-home COVID-19 test. (Press release here; Articles here and here)
  • AstraZeneca PLC asked federal regulators for an Emergency Use Authorization of its COVID-19 antibody cocktail. The treatment was 77 percent effective at preventing symptomatic illness in a clinical trial and could bolster protection for people who couldn’t get vaccinated or for whom the shots were less effective. (Articles here, here, here, and here)